BPTHのチャート
BPTHの企業情報
| symbol | BPTH |
|---|---|
| 会社名 | Bio-Path Holdings Inc. （バイオパス・ホ―ルディングス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Bio-Path Holdings Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology DNAbilize is a platform that uses P-ethoxy a deoxyribonucleic acid backbone modification. Its lead drug candidate Liposomal Grb2 (BP1001) targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate Liposomal Bcl2 (BP1002) targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors including triple negative breast cancer and inflammatory breast cancer. バイオパス・ホ―ルディングスは米国のバイオ医薬品企業の持株会社。子会社をとおして、主に癌治療候補剤リポソ―ムの開発を行う。急性骨髄性白血病、慢性骨髄性白血病、骨髄異形成症候群及び急性リンパ芽球性白血病を有する患者で臨床試験されている薬剤候補である。本社はテキサス州。 Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path's lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies. |
| 本社所在地 | 4710 Bellaire Boulevard Suite 210 Bellaire TX 77401 USA |
| 代表者氏名 | Peter Henry Nielsen ピーターヘンリーニールセン |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer Chief Financial Officer Treasurer |
| 電話番号 | +1 832-742-1357 |
| 設立年月日 | 36647 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 12人 |
| url | www.biopathholdings.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bpth |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -7.80800 |
| 終値（lastsale） | 0.55 |
| 時価総額（marketcap） | 7320408.15 |
| 時価総額 | 時価総額（百万ドル） 6.38485 |
| 売上高 | 売上高（百万ドル） 0.03700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 3.80685 |
| 当期純利益 | 当期純利益（百万ドル） -8.23400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Bio-Path Holdings Inc revenues was not reported. Net loss applicable to common stockholders increased 5% to $3.6M. Higher net loss reflects Change in fair value of warrant liabilit decrease from $2.4M (income) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.35 to -$0.32. |
BPTHのテクニカル分析
BPTHのニュース
Bio-Path Holdings Inc. (BPTH) Q4 2022 Earnings Call Transcript 2023/03/31 14:25:05 Seeking Alpha
Bio-Path Holdings Inc. (NASDAQ:NASDAQ:BPTH) Q4 2022 Earnings Conference Call March 31, 2023 8:30 AM ETCompany ParticipantsWill O''Connor - Stern IRPeter Nielsen - CEO and CFOAnthony Price -…
Bio-Path GAAP EPS of -$1.91 misses by $1.46 2023/03/31 11:02:55 Seeking Alpha
Bio-Path press release (BPTH): Q4 GAAP EPS of -$1.91 misses by $1.46.As of December 31, 2022, the Company had cash of $10.4 million, compared to $23.8 million at December 31, 2021
A Preview Of Bio-Path Holdings''s Earnings 2023/03/30 15:01:06 Benzinga
Bio-Path Holdings (NASDAQ: BPTH ) is set to give its latest quarterly earnings report on Friday, 2023-03-31. Here''s what investors need to know before the announcement. Analysts estimate that Bio-Path Holdings will report an earnings per share (EPS) of $-0.46. Bio-Path Holdings bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023 2023/03/24 20:01:00 GlobeNewswire
HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 31, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2022 and to provide a business overview.
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors 2022/12/07 12:00:00 GlobeNewswire
Phase 1/1b Clinical Trial Evaluating Ability of BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer Phase 1/1b Clinical Trial Evaluating Ability of BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer
Bio-Path Holdings Inc.''s (BPTH) CEO Peter Nielsen on Q2 2022 Results - Earnings Call Transcript 2022/08/16 15:34:21 Seeking Alpha
Bio-Path Holdings, Inc. (NASDAQ:NASDAQ:BPTH) Q2 2022 Earnings Conference Call August 16, 2022, 08:30 AM ET Company Participants Will O''Connor - Stern Investor Relations Peter Nielsen - CEO…
Bio-Path Holdings: Q2 Earnings Insights 2022/08/16 11:32:38 Benzinga
Bio-Path Holdings (NASDAQ: BPTH ) reported its Q2 earnings results on Tuesday, August 16, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Bio-Path Holdings beat estimated earnings by 14.29%, reporting … Full story available on Benzinga.com
Bio-Path GAAP EPS of -$0.42 beats by $0.07 (NASDAQ:BPTH) 2022/08/16 11:04:44 Seeking Alpha
Bio-Path press release (BPTH): Q2 GAAP EPS of -$0.42 beats by $0.07.As of June 30, 2022, the Company had cash of $17.0 million, compared to $23.8 million at December 31, 2021.
Bio-Path Holdings Reports Second Quarter 2022 Financial Results 2022/08/16 11:00:00 GlobeNewswire
Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET
Bio-Path: Q2 Earnings Snapshot 2022/08/16 10:59:37 mySA
BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Monday reported a loss of $3 million in its second quarter. On a per-share basis, the Bellaire, Texas-based company said it had a loss of 42 cents. The company''s shares closed at $4.13. A year ago, they were trading at $6.51. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPTH at https://www.zacks.com/ap/BPTH
Bio-Path Holdings: Q1 Earnings Insights 2022/05/17 11:46:58 Benzinga
Bio-Path Holdings (NASDAQ: BPTH ) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Bio-Path Holdings missed estimated earnings by 4.44%, reporting … Full story available on Benzinga.com
Bio-Path: Q1 Earnings Snapshot 2022/05/17 11:21:21 mySA
BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Monday reported a loss of $3.4 million in its first quarter. On a per-share basis, the Bellaire, Texas-based company said it had a loss of 47 cents. The company''s shares closed at $3.19. A year ago, they were trading at $5.33. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPTH at https://www.zacks.com/ap/BPTH
Bio-Path GAAP EPS of -$0.47 misses by $0.01 2022/05/17 11:04:12 Seeking Alpha
Bio-Path press release (BPTH): Q1 GAAP EPS of -$0.47 misses by $0.01.As of March 31, 2022, the Company had cash of $21.2 million, compared to $23.8 million as of December 31, 2021.
Bio-Path Holdings Reports First Quarter 2022 Financial Results 2022/05/17 11:00:00 GlobeNewswire
Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET
Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022 2022/05/10 11:00:00 GlobeNewswire
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, May 17, 2022 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2022 and to provide a business overview.